On this page
- What the literature contains
- Post-exertional malaise, and why travel is a problem
- Why uncontrolled results are worthless here
- The history that makes this worse
- What is typically offered
- Where research is genuinely going
- What helps in practice
- What a proper trial here would look like
- Questions worth asking
- Frequently asked questions
- Requesting a medical evaluation
Myalgic encephalomyelitis, also called chronic fatigue syndrome, is disabling, poorly understood and badly served by medicine. That combination makes it a target. Stem cell therapy for chronic fatigue syndrome has no controlled trial behind it — not a weak one, not a small one, none — and travelling for it carries a specific risk that applies to almost no other condition here.
What the literature contains
Searching for cell therapy trials in fatigue returns work in unrelated conditions where fatigue was measured as a symptom — for instance in liver failure — Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells.
That is not a study of chronic fatigue syndrome. It is a study of liver failure in which patients were evaluated clinically.
There is no trial to summarise here, favourable or otherwise. That absence is the finding, and it is the reason this page exists.
What the evidence levels mean explains why an empty search produces a page rather than silence.
Post-exertional malaise, and why travel is a problem
The defining feature of ME/CFS for most patients is that exertion makes them worse, often a day or two later, and often out of all proportion to what was done.
This is not ordinary tiredness and it does not respond to pushing through. It is a delayed, disproportionate worsening that can last days or weeks.
Long-haul flights, airports, time-zone shifts, unfamiliar heat, and a schedule of appointments are a concentrated dose of exactly the exertion that triggers it.
People travel for treatment and return worse. The deterioration is usually attributed to the illness rather than the journey, and the timing makes that impossible to disentangle. This should be said before anyone books anything.
Why uncontrolled results are worthless here
ME/CFS fluctuates substantially. Patients have better weeks and worse weeks, and most enquire about treatment during a bad period.
Anyone treated at their worst point will, on average, be better some weeks later, for reasons that have nothing to do with treatment. That is regression to the mean and it is powerful in relapsing conditions.
A proportion of people also improve over years without specific treatment, particularly those ill for a shorter time.
Testimonials from this condition therefore carry no information at all about whether a treatment works, however sincerely they are given.
The history that makes this worse
People with ME/CFS have been told for decades that their illness is psychological, that they are deconditioned, and that graded exercise will fix it. Much of that was wrong and some of it caused harm.
That history leaves people understandably distrustful of mainstream medicine and correspondingly open to anyone who takes the illness seriously and offers something concrete.
The sector selling infusions understands this and uses it. Taking a condition seriously is not the same as having a treatment for it, and the first does not license the second.
This page takes the illness entirely seriously. That is exactly why it does not pretend there is evidence.
What is typically offered
Intravenous infusions, generally bundled with vitamin drips, ozone therapy, hyperbaric oxygen, chelation or exosome products, under headings like immune reset or cellular energy restoration.
Exosome preparations are promoted particularly heavily for fatigue and are the least evidenced product on this site — exosome therapy.
Mitochondrial language features prominently. No test is offered that establishes a mitochondrial problem beforehand or its correction afterwards.
Prices are high and many patients in this group cannot work. That combination deserves to be stated rather than left implicit.
Where research is genuinely going
Serious work is under way on immune dysfunction, autonomic abnormalities, mitochondrial and metabolic changes, and persistent infection as possible mechanisms.
Long COVID has brought funding and attention to post-viral illness on a scale ME/CFS never received, and the two overlap substantially — post-viral recovery.
That research may eventually produce a treatment. It has not yet, and a mechanism under investigation is not a treatment available for purchase.
Clinical trials do recruit in this area, and entering one is a different proposition from paying a clinic.
What helps in practice
Pacing — managing activity to stay within limits rather than pushing to them — is what most specialist services now advise, and what most patients report as the thing that helps.
Treating identifiable components: orthostatic intolerance, sleep disturbance, pain, and any co-existing condition found on investigation.
Being properly assessed for other diagnoses that mimic this, several of which are treatable, is worth more than anything discussed above.
None of that is satisfying, and it is the honest current position.
What a proper trial here would look like
Randomised, placebo-controlled, with an agreed case definition — several exist and they select different populations, which is itself a problem the field has had to confront.
Outcomes measured objectively where possible. Actigraphy records actual movement over days rather than relying on recall, and repeat exercise testing on consecutive days captures post-exertional malaise in a way a questionnaire cannot.
Follow-up long enough to outlast natural fluctuation, which in this condition means many months rather than weeks.
None of that is impossible and some of it is being done for other treatments. It has not been done for cell therapy.
Questions worth asking
- Which controlled trial in ME/CFS supports this?
- Do I have post-exertional malaise, and what would travel do to it?
- What happens if I deteriorate while abroad, or cannot complete the treatment?
- What is the refund position if I become too unwell to travel?
Fibromyalgia and chronic pain covers an overlapping group, and the limits of current evidence sets out the wider pattern.
Frequently asked questions
Is there any trial in ME/CFS?
No controlled trial of cell therapy in this condition exists. Searching the literature directly returns nothing relevant.
Why is travelling risky for me specifically?
If you have post-exertional malaise, flights, airports and a schedule of appointments are exactly the cumulative exertion that provokes a crash.
People in forums say it helped them.
The condition fluctuates and most people seek treatment at their worst. Improvement weeks later is expected regardless of what was given.
What about mitochondrial treatments?
No test is offered that establishes a mitochondrial problem beforehand or demonstrates its correction afterwards. The language is not matched by measurement.
Is anyone researching this properly?
Yes — immune, autonomic, metabolic and post-viral mechanisms are all under active investigation, helped by long COVID funding. That is research, not treatment.
What should I do now?
Pacing, treating identifiable components, and being properly assessed for conditions that mimic this. Unsatisfying, and it is the honest position.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.